Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292474 · ClinicalTrials.gov registry record · Phase 2
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
A Phase 2 study of Coronary Artery Disease, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,326
- Enrollment target
- 1
- Study location
NCT00292474 is a Phase 2 study of Coronary Artery Disease that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,326 participants, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00292474, a Phase 2 study of Coronary Artery Disease, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,326 participants
- Enrollment target
- 1
- Study location
Study Summary
The ultimate goal of a paclitaxel eluting stent system (TAXUS stent) is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place. The purpose of the TAXUS IV-SR trial is to study the safety and efficacy of the TAXUS Stent under controlled trial circumstances used in the treatment of new coronary artery lesions (heart blockages) This clinical investigation will evaluate the safety and effectiveness of the TAXUS Stent with 1 ug/mm2 (loaded drug/stent surface area) of paclitaxel incorporated into a slow rate-release formulation of a triblock copolymer carrier system for treatment of new coronary artery lesions.
Conditions Studied
Interventions
- DEVICE percutaneous coronary intervention
Study Locations (1)
Ohio
- Stephen G.Ellis - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,326 participants |
| Start Date | 2002-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292474
The ClinicalTrials.gov registry entry for NCT00292474 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,326 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,281-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which percutaneous coronary intervention is the first listed.
NCT00292474 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00292474 about?
NCT00292474 is a clinical study titled "TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent". The ultimate goal of a paclitaxel eluting stent system (TAXUS stent) is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place. The purpose of the TAXUS IV-SR trial is to study the safety and efficac...
What is the current status of trial NCT00292474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,326 participants. The study started on 2002-03. Estimated completion is 2007-08.
What conditions does trial NCT00292474 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT00292474?
The interventions under investigation include: percutaneous coronary intervention (DEVICE).
Who is sponsoring clinical trial NCT00292474?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00292474 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
COMPLETED · Phase 2
-
MARS - Monitored Atherosclerosis Regression Study
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.